In nearly all cases, acromegaly is caused by excess GH from a pituitary adenoma, resulting in elevated circulating levels of GH and, subsequently, IGF-1. Treatment goals are to eliminate morbidity and restore the increased mortality to normal rates. Therapeutic strategies aim to minimize tumor mass and normalize GH and IGF-1 levels. Somatostatin analogues are the medical treatment of choice in acromegaly, as first-line or post-surgical therapy, and have proven efficacy in pituitary tumor volume reduction (TVR).
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly / Colao, Annamaria; Auriemma, RENATA SIMONA; Pivonello, Rosario. - In: PITUITARY. - ISSN 1386-341X. - 19:2(2015), pp. 210-221. [10.1007/s11102-015-0677-y]
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
COLAO, ANNAMARIA;AURIEMMA, RENATA SIMONA;PIVONELLO, ROSARIO
2015
Abstract
In nearly all cases, acromegaly is caused by excess GH from a pituitary adenoma, resulting in elevated circulating levels of GH and, subsequently, IGF-1. Treatment goals are to eliminate morbidity and restore the increased mortality to normal rates. Therapeutic strategies aim to minimize tumor mass and normalize GH and IGF-1 levels. Somatostatin analogues are the medical treatment of choice in acromegaly, as first-line or post-surgical therapy, and have proven efficacy in pituitary tumor volume reduction (TVR).I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.